Search

Search Constraints

You searched for: Author/Creator Oostvogels, Lidia

Search Results

1. 149. Immunogenicity, Safety, and Post-hoc Efficacy Assessment of the Adjuvanted Recombinant Zoster Vaccine in Adults with Hematologic Malignancies: A Phase 3, Randomized Clinical Trial. (26th November 2018)

2. 1956. Persistence of Immune Response and Safety of an Adjuvanted Recombinant Zoster Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: End-of-Study Results of a Phase III, Group-Matched, Clinical Trial. (26th November 2018)

3. 2482. Impact of a Recombinant Zoster Vaccine on Quality of Life: Data from a Randomized, Placebo-Controlled, Phase 3 Trial in Adult Hematopoietic Stem Cell Transplant Recipients. (26th November 2018)

4. 2483. Twelve-Month Immunogenicity and Safety of an Adjuvanted Recombinant Zoster Vaccine in Immunosuppressed Adults Post Renal Transplant: a Phase III Randomized Clinical Trial. (26th November 2018)

5. 2488. The Impact of Reactogenicity After Administration of the Recombinant Zoster Vaccine Upon the Physical Functioning and Quality of Life of Older Adults. (26th November 2018)

6. 5. How Does Frailty Impact the Efficacy, Reactogenicity, Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine? A Secondary Analysis of the ZOE-50 and ZOE-70 Studies. (31st December 2020)

8. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice. Issue 11 (2nd November 2021)

9. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany. Issue 10 (3rd October 2017)

10. Corrigendum to 'Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial' [Vaccine 36 (2018) 4278–4286]. Issue 9 (21st February 2019)